Linda de Munck
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Linda de Munck has a total of 272 co-authors. Here are the top co-authors by number of shared publications:
- Sabine Siesling
Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, the Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands
11 shared publications - Amanda K. L. Anderson
Biotheranostics Inc., A Hologic Company, San Diego, California
8 shared publications - Bo Nordenskjöld
Linköping University, Linköping, Sweden
8 shared publications - Esther Bastiaannet
Cancer Epidemiology, University of Zurich, Epidemiology, Biostatistics and Prevention Institute, CH-8001 Zurich, Switzerland
8 shared publications - Gerrit-Jan Liefers
Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
8 shared publications - Jenna Wong
Biotheranostics Inc., A Hologic Company, San Diego, California
8 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 14
Development of an algorithm to support cancer registry registration by identifying patients with metachronous metastases after primary breast cancer
- 30 October 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 14
Open AccessDevelopment of an algorithm to support cancer registry registration by identifying patients with metachronous metastases after primary breast cancer
- Open Access
- 29 December 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 62, 101574
Breast cancer incidence, by stage at diagnosis, and mortality in 21 European countries in the era of mammography screening: an international population-based study
- 29 December 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 62, 101574
Open AccessBreast cancer incidence, by stage at diagnosis, and mortality in 21 European countries in the era of mammography screening: an international population-based study
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Table 3 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Univariate and multivariate Fine–Gray regression analyses of BCI in the NCR cohort.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Univariate and multivariate Fine–Gray regression analyses of BCI in the NCR cohort.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Performance of the adjusted BCI model in the NCR cohort (A) overall and (B–D) in clinical subsets. G2/G3, grade 2/3; T1/T2, T stage 1/2.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Performance of the adjusted BCI model in the NCR cohort (A) overall and (B–D) in clinical subsets. G2/G3, grade 2/3; T1/T2, T stage 1/2.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Performance of the adjusted BCI model in the Stockholm cohorts. The new cutpoint for the BCI minimal-risk group was trained using the untreated patients. (A) Untreated and (B) TAM-treated. TAM, tamoxifen.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Performance of the adjusted BCI model in the Stockholm cohorts. The new cutpoint for the BCI minimal-risk group was trained using the untreated patients. (A) Untreated and (B) TAM-treated. TAM, tamoxifen.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Data from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Purpose:This study assessed the prognostic ability of the breast cancer index (BCI) to identify patients at a minimal risk (<5%) of 10-year distant recurrence (DR) who are unlikely to benefit from adjuvant endocrine therapy.Experimental Design:This prospective translational study included postmenopausal patients with early-stage, hormone receptor–positive N0 breast cancer from the Stockholm (STO-3) trial who underwent surgery alone (“untreated”) or surgery plus adjuvant tamoxifen (“treated”) and from the Netherlands Cancer Registry (surgery alone). The primary endpoint was time to DR. An adjusted BCI model with an additional cutpoint was developed, which stratified patients into four prognostic risk groups.Results:Across cohorts, 16% to 22% of patients were classified as minimal risk of 10-year DR. In the Stockholm untreated cohort (n = 283), risks in the minimal-, low-, intermediate-, and high-risk groups were 2.3%, 15.5% [hazard ratio, 4.71 (95% confidence interval, 1.09–20.29) vs. minimal risk], 19.8% [6.97 (1.61–30.18)], and 35.9% [13.21 (3.07–56.76)], respectively (P < 0.001). In the Stockholm treated cohort (n = 317), risks were 4.3%, 5.0% [1.16 (0.35–3.85)], 11.7% [2.45 (0.74–8.14)], and 21.1% [5.27 (1.72–16.16); P < 0.001]. In the Netherlands Cancer Registry cohort (n = 1245), risks were 4.5%, 7.5% [subdistribution hazard ratio, 1.67 (95% confidence interval, 0.81–3.45)], 10.3% [2.40 (1.14–5.03)], and 13.1% [3.13 (1.50–6.55); P = 0.005]. BCI risk scores provided additional independent information over standard prognostic factors (likelihood ratio, χ2 = 7.98; P = 0.004).Conclusions:The adjusted BCI model identified women with early-stage, hormone receptor–positive N0 breast cancer at a minimal risk of DR who may consider de-escalating adjuvant endocrine therapy.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Purpose:This study assessed the prognostic ability of the breast cancer index (BCI) to identify patients at a minimal risk (<5%) of 10-year distant recurrence (DR) who are unlikely to benefit from adjuvant endocrine therapy.Experimental Design:This prospective translational study included postmenopausal patients with early-stage, hormone receptor–positive N0 breast cancer from the Stockholm (STO-3) trial who underwent surgery alone (“untreated”) or surgery plus adjuvant tamoxifen (“treated”) and from the Netherlands Cancer Registry (surgery alone). The primary endpoint was time to DR. An adjusted BCI model with an additional cutpoint was developed, which stratified patients into four prognostic risk groups.Results:Across cohorts, 16% to 22% of patients were classified as minimal risk of 10-year DR. In the Stockholm untreated cohort (n = 283), risks in the minimal-, low-, intermediate-, and high-risk groups were 2.3%, 15.5% [hazard ratio, 4.71 (95% confidence interval, 1.09–20.29) vs. minimal risk], 19.8% [6.97 (1.61–30.18)], and 35.9% [13.21 (3.07–56.76)], respectively (P < 0.001). In the Stockholm treated cohort (n = 317), risks were 4.3%, 5.0% [1.16 (0.35–3.85)], 11.7% [2.45 (0.74–8.14)], and 21.1% [5.27 (1.72–16.16); P < 0.001]. In the Netherlands Cancer Registry cohort (n = 1245), risks were 4.5%, 7.5% [subdistribution hazard ratio, 1.67 (95% confidence interval, 0.81–3.45)], 10.3% [2.40 (1.14–5.03)], and 13.1% [3.13 (1.50–6.55); P = 0.005]. BCI risk scores provided additional independent information over standard prognostic factors (likelihood ratio, χ2 = 7.98; P = 0.004).Conclusions:The adjusted BCI model identified women with early-stage, hormone receptor–positive N0 breast cancer at a minimal risk of DR who may consider de-escalating adjuvant endocrine therapy.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Table 2 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Prognostic performance of the four BCI risk groups in Stockholm and NCR cohorts.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Prognostic performance of the four BCI risk groups in Stockholm and NCR cohorts.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Patient clinicopathologic characteristics in the Stockholm and NCR cohorts.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Patient clinicopathologic characteristics in the Stockholm and NCR cohorts.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
CONSORT diagram for patient selection in the NCR cohort.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
CONSORT diagram for patient selection in the NCR cohort.
- Open Access
- 27 March 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (11) , 2222-2229
Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Purpose: This study assessed the prognostic ability of the breast cancer index (BCI) to identify patients at a minimal risk (<5%) of 10-year distant recurrence (DR) who are unlikely to benefit from adjuvant endocrine therapy. Experimental Design: This prospective translational study included postmenopausal patients with early-stage, hormone receptor–positive N0 breast cancer from the Stockholm (STO-3) trial who underwent surgery alone (“untreated”) or surgery plus adjuvant tamoxifen (“treated”) and from the Netherlands Cancer Registry (surgery alone). The primary endpoint was time to DR. An adjusted BCI model with an additional cutpoint was developed, which stratified patients into four prognostic risk groups. Results: Across cohorts, 16% to 22% of patients were classified as minimal risk of 10-year DR. In the Stockholm untreated cohort (n = 283), risks in the minimal-, low-, intermediate-, and high-risk groups were 2.3%, 15.5% [hazard ratio, 4.71 (95% confidence interval, 1.09–20.29) vs. minimal risk], 19.8% [6.97 (1.61–30.18)], and 35.9% [13.21 (3.07–56.76)], respectively (P < 0.001). In the Stockholm treated cohort (n = 317), risks were 4.3%, 5.0% [1.16 (0.35–3.85)], 11.7% [2.45 (0.74–8.14)], and 21.1% [5.27 (1.72–16.16); P < 0.001]. In the Netherlands Cancer Registry cohort (n = 1245), risks were 4.5%, 7.5% [subdistribution hazard ratio, 1.67 (95% confidence interval, 0.81–3.45)], 10.3% [2.40 (1.14–5.03)], and 13.1% [3.13 (1.50–6.55); P = 0.005]. BCI risk scores provided additional independent information over standard prognostic factors (likelihood ratio, χ2 = 7.98; P = 0.004). Conclusions: The adjusted BCI model identified women with early-stage, hormone receptor–positive N0 breast cancer at a minimal risk of DR who may consider de-escalating adjuvant endocrine therapy.
- 27 March 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (11) , 2222-2229
Open AccessIdentification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Purpose: This study assessed the prognostic ability of the breast cancer index (BCI) to identify patients at a minimal risk (<5%) of 10-year distant recurrence (DR) who are unlikely to benefit from adjuvant endocrine therapy. Experimental Design: This prospective translational study included postmenopausal patients with early-stage, hormone receptor–positive N0 breast cancer from the Stockholm (STO-3) trial who underwent surgery alone (“untreated”) or surgery plus adjuvant tamoxifen (“treated”) and from the Netherlands Cancer Registry (surgery alone). The primary endpoint was time to DR. An adjusted BCI model with an additional cutpoint was developed, which stratified patients into four prognostic risk groups. Results: Across cohorts, 16% to 22% of patients were classified as minimal risk of 10-year DR. In the Stockholm untreated cohort (n = 283), risks in the minimal-, low-, intermediate-, and high-risk groups were 2.3%, 15.5% [hazard ratio, 4.71 (95% confidence interval, 1.09–20.29) vs. minimal risk], 19.8% [6.97 (1.61–30.18)], and 35.9% [13.21 (3.07–56.76)], respectively (P < 0.001). In the Stockholm treated cohort (n = 317), risks were 4.3%, 5.0% [1.16 (0.35–3.85)], 11.7% [2.45 (0.74–8.14)], and 21.1% [5.27 (1.72–16.16); P < 0.001]. In the Netherlands Cancer Registry cohort (n = 1245), risks were 4.5%, 7.5% [subdistribution hazard ratio, 1.67 (95% confidence interval, 0.81–3.45)], 10.3% [2.40 (1.14–5.03)], and 13.1% [3.13 (1.50–6.55); P = 0.005]. BCI risk scores provided additional independent information over standard prognostic factors (likelihood ratio, χ2 = 7.98; P = 0.004). Conclusions: The adjusted BCI model identified women with early-stage, hormone receptor–positive N0 breast cancer at a minimal risk of DR who may consider de-escalating adjuvant endocrine therapy.